Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

BACKGROUND: A vaccine against SARS-CoV-2 is of high urgency. Here the safety and immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of SARS-CoV-2 are described. METHODS: INO-4800 was evaluated in two groups of 20 participants, receiving either 1.0 mg or 2.0 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Tebas, Pablo, Yang, ShuPing, Boyer, Jean D., Reuschel, Emma L., Patel, Ami, Christensen-Quick, Aaron, Andrade, Viviane M., Morrow, Matthew P., Kraynyak, Kimberly, Agnes, Joseph, Purwar, Mansi, Sylvester, Albert, Pawlicki, Jan, Gillespie, Elisabeth, Maricic, Igor, Zaidi, Faraz I., Kim, Kevin Y., Dia, Yaya, Frase, Drew, Pezzoli, Patrick, Schultheis, Katherine, Smith, Trevor R.F., Ramos, Stephanie J., McMullan, Trevor, Buttigieg, Karen, Carroll, Miles W., Ervin, John, Diehl, Malissa C., Blackwood, Elliott, Mammen, Mammen P., Lee, Jessica, Dallas, Michael J., Brown, Ami Shah, Shea, Jacqueline E., Kim, J.Joseph, Weiner, David B., Broderick, Kate E., Humeau, Laurent M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759123/
https://www.ncbi.nlm.nih.gov/pubmed/33392485
http://dx.doi.org/10.1016/j.eclinm.2020.100689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759123/
https://www.ncbi.nlm.nih.gov/pubmed/33392485
http://dx.doi.org/10.1016/j.eclinm.2020.100689

Ejemplares similares